rljohnson on DSK3VPTVN1PROD with NOTICES

15790 Federal Register / Vol. 80, No. 57 / Wednesday, March 25, 2015 / Notices 


Obtaining Copies of Proposals: 

Requesters may obtain a copy of the 

information collection documents from 

the General Services Administration, 

Regulatory Secretariat Division (MVCB), 

1800 F Street NW., Washington, DC 

20405, telephone 202–501–4755. Please 

cite OMB Control No. 9000–0054, 

Submission for OMB Review; U.S.-Flag 

Air Carriers Statement, in all 

correspondence. 

Dated: March 19, 2015. 

Edward Loeb, 

Acting Director, Office of Government-wide 

Acquisition Policy, Office of Acquisition 

Policy, Office of Government-wide Policy. 

[FR Doc. 2015–06818 Filed 3–24–15; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Decision To Evaluate a Petition To 

Designate a Class of Employees From 

the Argonne National Laboratory-West 

in Scoville, Idaho, To Be Included in 

the Special Exposure Cohort 

AGENCY: National Institute for 

Occupational Safety and Health 

(NIOSH), Centers for Disease Control 

and Prevention, Department of Health 

and Human Services. 

ACTION: Notice. 

SUMMARY: NIOSH gives notice of a 

decision to evaluate a petition to 

designate a class of employees from the 

Argonne National Laboratory-West in 

Scoville, Idaho, to be included in the 

Special Exposure Cohort under the 

Energy Employees Occupational Illness 

Compensation Program Act of 2000. 

FOR FURTHER INFORMATION CONTACT: 

Stuart L. Hinnefeld, Director, Division 

of Compensation Analysis and Support, 

National Institute for Occupational 

Safety and Health, 1090 Tusculum 

Avenue, MS C–46, Cincinnati, OH 

45226–1938, Telephone 877–222–7570. 

Information requests can also be 

submitted by email to DCAS@CDC.GOV. 

SUPPLEMENTARY INFORMATION: 

Authority: 42 CFR 83.9–83.12. 

Pursuant to 42 CFR 83.12, the initial 

proposed definition for the class being 

evaluated, subject to revision as 

warranted by the evaluation, is as 

follows: 

Facility: Argonne National 

Laboratory-West. 

Location: Scoville, Idaho. 

Job Titles and/or Job Duties: All 

workers who worked in any location. 

Period of Employment: April 10, 1951 

through December 31, 1979. 

John Howard, 

Director, National Institute for Occupational 

Safety and Health. 

[FR Doc. 2015–06786 Filed 3–24–15; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 


AGENCY: National Institutes of Health, 


HHS. 


ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 209 and 37 CFR part 404 to 

achieve expeditious commercialization 

of results of federally-funded research 

and development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Licensing information and copies of the 

U.S. patent applications listed below 

may be obtained by writing to the 

indicated licensing contact at the Office 

of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301– 

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology descriptions follow. 

Engineered Antibody Domains With 

Increased FcRn Binding and in vivo 

Half-Life 

Description of Technology: 

Monoclonal antibodies (mAbs) are a fast 

growing class of new therapeutic 

molecules. However, their large size 

remains a significant challenge, 

preventing them from targeting 

sterically restricted epitopes and 

efficiently penetrating into tissues. 

Smaller antibody fragments and 

engineered variants are under 

development to address this challenge, 

but to date their therapeutic 

applications have been limited due to 

rapid clearance and short half-life 

which greatly decrease their efficacy in 

vivo. 

This technology describes two 

antibody constant domains or binders 

with increased FcRn binding and in vivo 

half-life. In addition, these binders are 

small in size (16kDa), very stable, and 

can be efficiently expressed in E. coli. 

As a result, the binders are particularly 

well suited as scaffolds for the 

generation of antibody libraries, from 

which a desired antigen binders could 

be developed into therapeutic products 

with much greater potency compared to 

existing mAbs. They could also be used 

as fusion partners to extend the half-life 

of candidate protein therapeutics. 

Potential Commercial Applications 

• Antibody scaffolds for library 

construction, and the generation of 

therapeutics against various diseases. 

• Fusion partners to extend the halflife of candidate protein therapeutics. 

Competitive Advantages 

• Small (16kD) size for better tissue 

penetration, and in the case of fusion 

proteins, reduced steric hindrance for 

therapeutic activity. 

• Superior stability compared to 

isolated CH2 domains and stability 

comparable to or higher than that of an 

isolated Fc fragment. 

• Exhibit greatly enhanced FcRn 

binding abilities, including more potent 

transcytosis and longer in vivo half-life. 

• Can be efficiently expressed in E. 

coli. 

Development Stage 

• Early-stage 

• In vitro data available 

• In vivo data available (animal) 

Inventors: Dimiter Dimitrov and 

Tianlei Ying (NCI). 

Intellectual Property: HHS Reference 

No. E–136–2014/0—US Provisional 

Application No. 62/022,810 filed July 

10, 2014. 

Licensing Contact: Whitney Hastings, 

Ph.D.; 301–451–7337; hastingw@ 

mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate or 

commercialize Engineered Antibody 

Domains. For collaboration 

opportunities, please contact John D. 

Hewes, Ph.D. at john.hewes@nih.gov or 

240–276–5515. 

CXCR4 Reduction Leads to 

Enhancement of Engraftment of 

Hematopoietic Stem Cells 

Description of Technology: Methods 

of enhancing engraftment of donor 

hematopoietic stem cells (HSCs) by 

reducing expression or activity of